RNS REACH
Verici Dx plc
("Verici Dx" or the "Company")
Product rebranding as Tutivia™
Verici Dx's post-transplant test, Tuteva, to be rebranded as Tutivia™
Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that its post-transplant blood test focused on acute rejection, has been rebranded as Tutivia™.
Tutivia™ (formerly known as Tuteva), is a blood-based RNA signature for a risk score for acute rejection, and will be the first test commercialised on the Verici transplant biomarker platform, with a soft commercial launch in the United States expected later in 2022.
The first three products on the platform are:
· Clarava™, a pre-transplant prognosis test for the risk of early acute rejection;
· Tutivia™, a post-transplant test focused upon acute rejection, including sub-clinical rejection; and
· Protega™, a post-transplant test that aims to predict the risk of fibrosis and long-term graft failure
Enquiries:
| Verici Dx | |
| Sara Barrington, CEO | Via Walbrook PR |
| Julian Baines, Chairman |
|
| | |
| Singer Capital Markets (Nominated Adviser & Broker) | Tel: 020 7496 3000 |
| Aubrey Powell / Kailey Aliyar / Sam Butcher | |
| | |
| Walbrook PR Limited | Tel: 020 7933 8780 or vericidx@walbrookpr.com |
| Paul McManus / Sam Allen | Mob: 07980 541 893 / 07502 558 258 |
About Reach announcements
Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.
About Verici Dx plc www.vericidx.com
Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage. The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology, including through collaboration with medical device, biopharmaceutical and data science partners.
The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.